Inversago Pharma

Inversago Pharma is a Canadian biopharmaceutical company focused on the development of innovative therapies for the treatment of metabolic diseases, including obesity and metabolic syndrome. The company is dedicated to addressing unmet medical needs in these areas through its research and development efforts.

Inversago Pharma specializes in targeting the peripheral cannabinoid receptor type 1 (CB1) pathway. The CB1 receptor is involved in regulating various physiological processes, including appetite, metabolism, and energy balance. By modulating this pathway, Inversago Pharma aims to develop novel therapeutics to help manage and potentially treat metabolic disorders.

When Inversago Pharma raised a Series C financing worth roughly $70 million ($95 million CAD), it garnered media attention in October 2022. The company will use the money from the round to develop medication for problems of obesity and hypertriglyceridemia, type 1 and type 2 diabetes, non-alcoholic steatohepatitis, diabetic kidney disease, and more. The start of a phase 2 study is anticipated for late 2022.

Drugs from Inversago that inhibit the cannabinoid receptor type 1 (CB1) protein are being developed to treat metabolic disorders. This protein, which affects functions including hunger and blood sugar regulation, is brought on by the body's own cannabinoids.

Headquarters: Montreal
Founded: 2015

Website: https://inversago.com/en/